APO RESEARCH · REPORT
Oncolytic Virus Therapy
Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.
Product & engineering
Understand the product.
Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.
Selected research
Industry Growth & Trends
Global Oncolytic Virus Therapy Industry Growth and Trends Forecast to 2032
Market perspective
Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.
According to APO Research, the global Oncolytic Virus Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
Report Scope
Read the full market overview
This report provides a structured, data-driven view of the global Oncolytic Virus Therapy market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Oncolytic Virus Therapy market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Oncolytic Virus Therapy market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Oncolytic Virus Therapy.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Oncolytic Virus Therapy market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Oncolytic Virus Therapy Market by Company
Amgen
Oncolytics Biotech
Viralytics
Transgene SA
Oncolys BioPharma
Targovax
PsiOxus Therapeutics
SillaJen Biotherapeutics
Sorrento Therapeutics
Lokon Pharma
Genelux Corporation
Vyriad
TILT Biotherapeutics
Cold Genesys
Oncolytic Virus Therapy Segment by Type
HSV-based Oncolytic Viruses
Adenoviruses-based Oncolytic Viruses
Vaccinia Virus-based Oncolytic Viruses
Vesicular Stomatitis Virus-based Oncolytic Viruses
Newcastle Disease Virus-based Oncolytic Viruses
Oncolytic Virus Therapy Segment by Application
Melanoma
Prostate Cancer
Breast Cancer
Ovarian Cancer
Others
Oncolytic Virus Therapy Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncolytic Virus Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oncolytic Virus Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncolytic Virus Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Oncolytic Virus Therapy companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- HSV-based Oncolytic Viruses
- Adenoviruses-based Oncolytic Viruses
- Vaccinia Virus-based Oncolytic Viruses
- Vesicular Stomatitis Virus-based Oncolytic Viruses
- Newcastle Disease Virus-based Oncolytic Viruses
Applications
- Melanoma
- Prostate Cancer
- Breast Cancer
- Ovarian Cancer
- Others
Companies covered
- Amgen
- Oncolytics Biotech
- Viralytics
- Transgene SA
- Oncolys BioPharma
- Targovax
- PsiOxus Therapeutics
- SillaJen Biotherapeutics
- Sorrento Therapeutics
- Lokon Pharma
- Genelux Corporation
- Vyriad
- TILT Biotherapeutics
- Cold Genesys
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Oncolytic Virus Therapy Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Oncolytic Virus Therapy Market Size by Region (2021-2032)
- 1.4.1 Global Oncolytic Virus Therapy Market Size by Region (2021-2026)
- 1.4.2 Global Oncolytic Virus Therapy Market Size by Region (2027-2032)
- 1.5 Key Regions Oncolytic Virus Therapy Market Size (2021-2032)
- 1.5.1 North America Oncolytic Virus Therapy Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Oncolytic Virus Therapy Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Oncolytic Virus Therapy Market Size Growth Rate (2021-2032)
- 1.5.4 South America Oncolytic Virus Therapy Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Oncolytic Virus Therapy Market Size Growth Rate (2021-2032)
2 Oncolytic Virus Therapy Market by Type
- 2.1 Type Introduction
- 2.1.1 HSV-based Oncolytic Viruses
- 2.1.2 Adenoviruses-based Oncolytic Viruses
- 2.1.3 Vaccinia Virus-based Oncolytic Viruses
- 2.1.4 Vesicular Stomatitis Virus-based Oncolytic Viruses
- 2.1.5 Newcastle Disease Virus-based Oncolytic Viruses
- 2.2 Global Oncolytic Virus Therapy Market Size by Type
- 2.2.1 Global Oncolytic Virus Therapy Market Size Overview by Type (2021-2032)
- 2.2.2 Global Oncolytic Virus Therapy Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Oncolytic Virus Therapy Market Size Forecasted by Type (2027-2032)
- 2.3 Global Oncolytic Virus Therapy Market Size by Regions
- 2.3.1 North America Oncolytic Virus Therapy Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Oncolytic Virus Therapy Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Oncolytic Virus Therapy Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Oncolytic Virus Therapy Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Oncolytic Virus Therapy Market Size Breakdown by Type (2021-2026)
3 Oncolytic Virus Therapy Market by Application
- 3.1 Type Introduction
- 3.1.1 Melanoma
- 3.1.2 Prostate Cancer
- 3.1.3 Breast Cancer
- 3.1.4 Ovarian Cancer
- 3.1.5 Others
- 3.2 Global Oncolytic Virus Therapy Market Size by Application
- 3.2.1 Global Oncolytic Virus Therapy Market Size Overview by Application (2021-2032)
- 3.2.2 Global Oncolytic Virus Therapy Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Oncolytic Virus Therapy Market Size Forecasted by Application (2027-2032)
- 3.3 Global Oncolytic Virus Therapy Market Size by Regions
- 3.3.1 North America Oncolytic Virus Therapy Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Oncolytic Virus Therapy Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Oncolytic Virus Therapy Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Oncolytic Virus Therapy Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Oncolytic Virus Therapy Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Oncolytic Virus Therapy Industry Trends
- 4.2 Oncolytic Virus Therapy Industry Drivers
- 4.3 Oncolytic Virus Therapy Industry Opportunities and Challenges
- 4.4 Oncolytic Virus Therapy Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Oncolytic Virus Therapy Revenue (2021-2026)
- 5.2 Global Oncolytic Virus Therapy Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Oncolytic Virus Therapy Key Company Headquarters & Area Served
- 5.4 Global Oncolytic Virus Therapy Company, Product Type & Application
- 5.5 Global Oncolytic Virus Therapy Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Oncolytic Virus Therapy Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Oncolytic Virus Therapy Players Market Share by Revenue in 2025
- 5.6.3 2025 Oncolytic Virus Therapy Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Amgen
- 6.1.1 Amgen Company Information
- 6.1.2 Amgen Business Overview
- 6.1.3 Amgen Oncolytic Virus Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Amgen Oncolytic Virus Therapy Product Portfolio
- 6.1.5 Amgen Recent Developments
- 6.2 Oncolytics Biotech
- 6.2.1 Oncolytics Biotech Company Information
- 6.2.2 Oncolytics Biotech Business Overview
- 6.2.3 Oncolytics Biotech Oncolytic Virus Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Oncolytics Biotech Oncolytic Virus Therapy Product Portfolio
- 6.2.5 Oncolytics Biotech Recent Developments
- 6.3 Viralytics
- 6.3.1 Viralytics Company Information
- 6.3.2 Viralytics Business Overview
- 6.3.3 Viralytics Oncolytic Virus Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Viralytics Oncolytic Virus Therapy Product Portfolio
- 6.3.5 Viralytics Recent Developments
- 6.4 Transgene SA
- 6.4.1 Transgene SA Company Information
- 6.4.2 Transgene SA Business Overview
- 6.4.3 Transgene SA Oncolytic Virus Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Transgene SA Oncolytic Virus Therapy Product Portfolio
- 6.4.5 Transgene SA Recent Developments
- 6.5 Oncolys BioPharma
- 6.5.1 Oncolys BioPharma Company Information
- 6.5.2 Oncolys BioPharma Business Overview
- 6.5.3 Oncolys BioPharma Oncolytic Virus Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Oncolys BioPharma Oncolytic Virus Therapy Product Portfolio
- 6.5.5 Oncolys BioPharma Recent Developments
- 6.6 Targovax
- 6.6.1 Targovax Company Information
- 6.6.2 Targovax Business Overview
- 6.6.3 Targovax Oncolytic Virus Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Targovax Oncolytic Virus Therapy Product Portfolio
- 6.6.5 Targovax Recent Developments
- 6.7 PsiOxus Therapeutics
- 6.7.1 PsiOxus Therapeutics Company Information
- 6.7.2 PsiOxus Therapeutics Business Overview
- 6.7.3 PsiOxus Therapeutics Oncolytic Virus Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 PsiOxus Therapeutics Oncolytic Virus Therapy Product Portfolio
- 6.7.5 PsiOxus Therapeutics Recent Developments
- 6.8 SillaJen Biotherapeutics
- 6.8.1 SillaJen Biotherapeutics Company Information
- 6.8.2 SillaJen Biotherapeutics Business Overview
- 6.8.3 SillaJen Biotherapeutics Oncolytic Virus Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 SillaJen Biotherapeutics Oncolytic Virus Therapy Product Portfolio
- 6.8.5 SillaJen Biotherapeutics Recent Developments
- 6.9 Sorrento Therapeutics
- 6.9.1 Sorrento Therapeutics Company Information
- 6.9.2 Sorrento Therapeutics Business Overview
- 6.9.3 Sorrento Therapeutics Oncolytic Virus Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Sorrento Therapeutics Oncolytic Virus Therapy Product Portfolio
- 6.9.5 Sorrento Therapeutics Recent Developments
- 6.10 Lokon Pharma
- 6.10.1 Lokon Pharma Company Information
- 6.10.2 Lokon Pharma Business Overview
- 6.10.3 Lokon Pharma Oncolytic Virus Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Lokon Pharma Oncolytic Virus Therapy Product Portfolio
- 6.10.5 Lokon Pharma Recent Developments
- 6.11 Genelux Corporation
- 6.11.1 Genelux Corporation Company Information
- 6.11.2 Genelux Corporation Business Overview
- 6.11.3 Genelux Corporation Oncolytic Virus Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Genelux Corporation Oncolytic Virus Therapy Product Portfolio
- 6.11.5 Genelux Corporation Recent Developments
- 6.12 Vyriad
- 6.12.1 Vyriad Company Information
- 6.12.2 Vyriad Business Overview
- 6.12.3 Vyriad Oncolytic Virus Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Vyriad Oncolytic Virus Therapy Product Portfolio
- 6.12.5 Vyriad Recent Developments
- 6.13 TILT Biotherapeutics
- 6.13.1 TILT Biotherapeutics Company Information
- 6.13.2 TILT Biotherapeutics Business Overview
- 6.13.3 TILT Biotherapeutics Oncolytic Virus Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 TILT Biotherapeutics Oncolytic Virus Therapy Product Portfolio
- 6.13.5 TILT Biotherapeutics Recent Developments
- 6.14 Cold Genesys
- 6.14.1 Cold Genesys Company Information
- 6.14.2 Cold Genesys Business Overview
- 6.14.3 Cold Genesys Oncolytic Virus Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Cold Genesys Oncolytic Virus Therapy Product Portfolio
- 6.14.5 Cold Genesys Recent Developments
7 North America
- 7.1 North America Oncolytic Virus Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Oncolytic Virus Therapy Market Size by Country (2021-2026)
- 7.3 North America Oncolytic Virus Therapy Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Oncolytic Virus Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Oncolytic Virus Therapy Market Size by Country (2021-2026)
- 8.3 Europe Oncolytic Virus Therapy Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Oncolytic Virus Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Oncolytic Virus Therapy Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Oncolytic Virus Therapy Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Oncolytic Virus Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Oncolytic Virus Therapy Market Size by Country (2021-2026)
- 10.3 South America Oncolytic Virus Therapy Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Oncolytic Virus Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Oncolytic Virus Therapy Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Oncolytic Virus Therapy Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst